In normal physiology, vascular endothelial growth factor (VEGF) plays a crucial role in vascular regeneration. However, in tumor cells, VEGF can stimulate angiogenesis, giving tumors exceptional growth capability.VEGF activates VEGF signaling in endothelial cells by binding to VEGF receptor tyrosine kinase, stimulating endothelial cell proliferation and survival, increasing vascular permeability, and sustaining tumor growth metabolism. KDR (Kinase Insert Domain Receptor) encodes the VEGFR2 receptor. Vascular inhibitors targeting the VEGF and its receptor signaling pathways are widely used in anti-tumor therapy. In recent years, scientists have also been developing a range of combination therapies targeting both VEGF and immune checkpoints.The VEGF Reporter 293 Cell Line is a luciferase reporter gene cell line constructed based on the transcription factor signaling pathway. When VEGF binds to the VEGFR2 receptor, it activates the transcription factor signaling pathway, thereby inducing the expression of luciferase. Luciferase readings reflect the activation of the signaling pathway, making it suitable for evaluating the in vitro effects of VEGF-related drugs.
